argenx SE reported 2.09B in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
AstraZeneca USD 7.06B 1.83B Jun/2025
Galapagos EUR 108.07M 43.83M Mar/2025
Genmab DKK 1.3B 323M Jun/2025
GlaxoSmithKline GBP 3.6B 865M Jun/2025
GRIFOLS EUR 558.69M 194.13M Jun/2025
Hikma Pharmaceutical USD 188M 188M Dec/2024
Qiagen NV USD 733.82M 95.06M Jun/2025
UCB EUR 1.57B 1.14B Dec/2024